Lineage Cell Therapeutics, Inc. (LCTX)
NYSE American · Manufacturing · Biological products, (no diagnostic substances)
LCTX price, last 12 months
Key stats
- Previous close
- $0.9478
- Open
- $0.9500
- Day range
- $0.9419 – $1.05
- 52-week range
- $0.9101 – $2.09
- Volume
- 2.4M
- Avg volume (20 days)
- 1.4M
- Market cap
- $260.5M
Performance
Technicals and fundamentals
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NYSE American
- Market cap
- $260.5M